切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2022, Vol. 12 ›› Issue (04) : 236 -240. doi: 10.3877/cma.j.issn.2095-2015.2022.04.010

综述

食管-胃底静脉曲张破裂出血内镜治疗后再出血高危因素研究进展
刘黎明1, 张春清2,()   
  1. 1. 250021 济南,山东大学附属省立医院消化内科
    2. 250021 济南,山东大学附属省立医院消化内科;250021 济南,山东第一医科大学附属省立医院消化内科
  • 收稿日期:2021-12-15 出版日期:2022-08-01
  • 通信作者: 张春清
  • 基金资助:
    国家自然科学基金面上项目(81970533); 国家自然科学基金青年课题(82000566)

Advances in high risk factors of rebleeding after endoscopic treatment of esophagogastric variceal bleeding

Liming Liu1, Chunqing Zhang2,()   

  1. 1. Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
    2. Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China; Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
  • Received:2021-12-15 Published:2022-08-01
  • Corresponding author: Chunqing Zhang
引用本文:

刘黎明, 张春清. 食管-胃底静脉曲张破裂出血内镜治疗后再出血高危因素研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2022, 12(04): 236-240.

Liming Liu, Chunqing Zhang. Advances in high risk factors of rebleeding after endoscopic treatment of esophagogastric variceal bleeding[J/OL]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 236-240.

食管-胃底静脉曲张破裂出血(EGVB)是肝硬化门静脉高压常见的并发症,标准药物和内镜治疗后仍有较高再出血率和死亡率。研究发现,Child-Pugh C级、中重度腹水、门静脉血栓(PVT)、曲张静脉套扎环数较多、食管静脉曲张范围较大、门静脉高压性胃病、凝血酶原时间(PT)>18 s、血红蛋白(HGB)水平较低、国际标准化比值(INR)较高和低蛋白血症是EGVB内镜治疗6周内再出血的独立危险因素,除HGB水平、腹水程度、Child-Pugh分级外,糖尿病、酒精性肝硬化、肝癌、谷草转氨酶(GOT)水平、肝硬度(LSM)及基于4因子纤维化指数(FIB-4)、白蛋白-胆红素(ALBI)评分可作为EGVB内镜治疗6周后再出血的独立预测因素。根据以上因素及评分系统,可筛选出EGVB内镜治疗后再出血高危患者,实施选择性干预措施,降低再出血率,改善预后。本文对肝硬化EGVB及特殊类型胃静脉曲张破裂出血(GVB)内镜治疗后早期及远期再出血的影响因素和高风险人群进行综述。

Esophago-gas-tric fundal varices bleeding (EGVB) is a common complication of portal hypertension in cirrhosis, which still has high rebleeding rate and mortality after standard drug and endoscopic treatment. The studies have found that Child-Pugh grade C, moderate to severe ascites, portal vein thrombosis (PVT), more ligature rings, larger range of esophageal varices, portal hypertensive gastropathy, prothrombin time (PT) >18 s, lower hemoglobin (HGB), higher international standardized ratio (INR) and hypoproteinemia are independent risk factors for rebleeding within 6 weeks after endoscopic therapy. In addition to HGB level, ascites degree and Child-Pugh grade, diabetes, alcoholic liver cirrhosis, liver cancer, aspartate aminotransferase (AST), liver stiffness measurement (LSM), and fibrosis 4 score (FIB-4) and albumin-bilirubin (ALBI) score are independent predictors of long-term rebleeding after 6 weeks of endoscopic therapy. According to the above factors and scoring system, patients with high risk of rebleeding can be screened, and selective intervention measures can be implemented to reduce the rebleeding rate and improve the prognosis. This review summarizes the influencing factors and high-risk populations for early and long-term rebleeding after endoscopic treatment of cirrhotic esophagogastric varices and special types of gastric varices.

1
中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版) [J]. 中华消化外科杂志, 2019, 18(2): 1087-1093.
2
Ferguson JW, Hayes PC. Transjugular intrahepatic portosystemic shunt in the prevention of rebleeding in oesophageal varices [J]. Eur J Gastroenterol Hepatol, 2006, 18(11): 1167-1171.
3
D'Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators [J]. Hepatology, 2003, 38(3): 599-612.
4
Harewood GC, Baron TH, Song LM. Factors predicting success of endoscopic variceal ligation for secondary prophylaxis of esophageal variceal bleeding [J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 2): 237-241.
5
Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017 [J]. Liver Int, 2017, 37 Suppl 1: 104-115.
6
Ma L, Tseng Y, Luo T, et al. Risk stratification for secondary prophylaxis of gastric varices due to portal hypertension [J]. Dig Liver Dis, 2019, 51(12): 1678-1684.
7
Bosch J, García-Pagán JC. Prevention of variceal rebleeding [J]. Lancet, 2003, 361(9361): 952-954.
8
Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis [J]. Gastroenterology, 2002, 123(4): 1013-1019.
9
D'Amico M, Berzigotti A, Garcia-Pagan JC. Refractory acute variceal bleeding: what to do next? [J]. Clin Liver Dis, 2010, 14(2): 297-305.
10
连佳,韩涛,向慧玲, 等. 肝硬化食管胃静脉曲张出血患者胃镜治疗术后再出血的影响因素分析 [J]. 临床肝胆病杂志, 2021, 37(9): 2092-2096.
11
Hunter SS, Hamdy S. Predictors of early re-bleeding and mortality after acute variceal haemorrhage [J]. Arab J Gastroenterol, 2013, 14(2): 63-67.
12
Abraldes JG, Villanueva C, Bañares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy [J]. J Hepatol, 2008, 48(2): 229-236.
13
Amitrano L, Guardascione MA, Manguso F, et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors [J]. Am J Gastroenterol, 2012, 107(12): 1872-1878.
14
Majid S, Azam Z, Shah HA, et al. Factors determining the clinical outcome of acute variceal bleed in cirrhotic patients [J]. Indian J Gastroenterol, 2009, 28(3): 93-95.
15
Jiménez Rosales R, Martínez-Cara JG, Vadillo-Calles F, et al. Analysis of rebleeding in cases of an upper gastrointestinal bleed in a single center series [J]. Rev Esp Enferm Dig, 2019, 111(3): 189-192.
16
Xu L, Ji F, Xu QW, et al. Risk factors for predicting early variceal rebleeding after endoscopic variceal ligation [J]. World J Gastroenterol, 2011, 17(28): 3347-3352.
17
郭雅丽,徐宝宏,刘贤, 等. 食管静脉曲张内镜治疗术后早期再出血的危险因素分析 [J]. 中华消化内镜杂志, 2018, 35(2): 89-93.
18
黄超,苏宁,吴胜兰. 内镜下食管静脉曲张套扎术后早期再出血的危险因素分析 [J]. 临床内科杂志, 2019, 36(4): 264-266.
19
张妍,丁惠国. 肝硬化食管静脉曲张内镜治疗术后早期再出血的危险因素分析 [J]. 临床肝胆病杂志, 2021, 37(9): 2087-2091.
20
Berreta J, Kociak D, Corti R, et al. [Predictors of intrahospitalary mortality in the upper gastrointestinal variceal bleeding due to chronic liver disease treated endoscopically] [J]. Acta Gastroenterol Latinoam, 2008, 38(1): 43-50.
21
Lata J, Husová L, Juránková J, et al. Factors participating in the development and mortality of variceal bleeding in portal hypertension possible effects of the kidney damage and malnutrition [J]. Hepatogastroenterology, 2006, 53(69): 420-425.
22
Lee SW, Lee TY, Chang CS. Independent factors associated with recurrent bleeding in cirrhotic patients with esophageal variceal hemorrhage [J]. Dig Dis Sei, 2009, 54(5): 1128-1134.
23
Banerjee A, Bishnu S, Dhali GK. Acute upper gastrointestinal bleed: An audit of the causes and outcomes from a tertiary care center in eastern India [J]. Indian J Gastroenterol, 2019, 38(3): 190-202.
24
Chandnani S, Rathi P, Udgirkar SS, et al. Clinical Utility of Risk Scores in Variceal Bleeding [J]. Arq Gastroenterol, 2019, 56(3): 286-293.
25
王曦,梅雪灿,张娜, 等.糖尿病对肝硬化食管静脉曲张内镜治疗后再出血影响的临床研究 [J]. 中华消化内镜杂志, 2020, 37(1): 33-37.
26
缪青,陈世耀,罗添成, 等. 内镜下组织黏合剂预防食管胃底静脉曲张出血的影响因素及疗效分析 [J]. 中华消化杂志, 2012, 32(12):818-821.
27
Ray-Offor E, Opusunju K. Re-bleed and Mortality Amongst Patients Following Initial Endoscopy for Upper Gastrointestinal Bleeding: A Single-Center Nigeria Study [J]. Cureus, 2021, 13(1): e12939.
28
曹影影,韩涛,张钰, 等. 肝硬化重度食管胃静脉曲张治疗后再出血及5年预后影响因素分析 [J]. 临床肝胆病杂志, 2021, 37(6): 1326-1330.
29
Agarwal S, Sharma S, Anand A, et al. Liver stiffness assessment as an alternative to hepatic venous pressure gradient for predicting rebleed after acute variceal bleed: A proof-of-concept study [J]. JGH Open, 2020, 5(1): 73-80.
30
Roberts D, Best LM, Freeman SC, et al. Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis [J]. Cochrane Database Syst Rev, 2021, 4(4): CD013155.
31
Plaz Torres MC, Best LM, Freeman SC, et al. Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network metaanalysis [J]. Cochrane Database Syst Rev, 2021, 3: CD013122.
32
Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis [J]. Hepatology, 2017, 66(4): 1219-1231.
33
Kitamoto M, Imamura M, Kamada K, et al. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage [J]. AJR Am J Roentgenol, 2002, 178(5): 1167-1174.
34
Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients [J]. Hepatology, 1992, 16(6): 1343-1349.
35
Zhou J, Liu C, Ma L, et al. Complications and management of elective endoscopic cyanoacrylate injection with lauromacrogol for gastric varices [J]. Eur J Gastroenterol Hepatol, 2021, 33(5): 680-685.
36
Tseng Y, Ma L, Luo T, et al. Patient Response to Endoscopic Therapy for Gastroesophageal Varices Based on Endoscopic Ultrasound Findings [J]. Gut Liver, 2018, 12(5): 562-570.
37
Zeng XQ, Ma LL, Tseng YJ, et al. Endoscopic cyanoacrylate injection with or without lauromacrogol for gastric varices: A randomized pilot study [J]. J Gastroenterol Hepatol, 2017, 32(3): 631-638.
38
Zanetto A, Garcia-Tsao G. Management of acute variceal hemorrhage [J]. F1000Res, 2019, 8: F1000 Faculty Rev-966.
39
Khashab MA, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy [J]. Gastrointest Endosc, 2015, 81(1): 81-89.
40
Mukkada RJ, Antony R, Chooracken MJ, et al. Endoscopic ultrasoundguided coil or glue injection in post-cyanoacrylate gastric variceal rebleed [J]. Indian J Gastroenterol, 2018, 37(2): 153-159.
41
张明艳,金苏云,孙若楠, 等. 钛夹辅助下内镜组织胶注射治疗胃静脉曲张 [J/CD]. 中华消化病与影像杂志(电子版), 2019, 9(6): 252-255.
[1] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[2] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[3] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[4] 贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[5] 林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[6] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[7] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[8] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[9] 蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[10] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[11] 吴广迎, 张延娟, 秦鹏, 卢艳丽. 经颈静脉肝内门体静脉分流术预防上消化道出血的临床研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 545-548.
[12] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
[13] 李文哲, 王毅, 崔建, 郑启航, 王靖彦, 于湘友. 新疆维吾尔自治区重症患者急性肾功能异常的危险因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 269-276.
[14] 刘志超, 胡风云, 温春丽. 山西省脑卒中危险因素与地域的相关性分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 424-433.
[15] 曹亚丽, 高雨萌, 张英谦, 李博, 杜军保, 金红芳. 儿童坐位不耐受的临床进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 510-515.
阅读次数
全文


摘要